General

MeiraGTx Secures FDA RMAT Designation for Groundbreaking Parkinson’s Gene Therapy

May 9, 2025

Written by Curation

Disclaimer: This article is sponsored by MeiraGTx.

This article is for informational purposes only, it should not be considered financial advice. Investing in biotechnology involves substantial risk, including the possibility of complete loss. Always consult a qualified financial advisor before making any investment decisions.

MeiraGTx Secures FDA RMAT Designation for Groundbreaking Parkinson’s Gene Therapy

What?

MeiraGTx has been granted the Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA for its AAV-GAD gene therapy, aimed at treating Parkinson’s disease (press release) This designation follows positive results from three clinical trials, which showed that AAV-GAD could provide a one-time treatment to target the brain’s dysfunctional circuits, potentially altering the disease’s progression, not just treating symptoms.

Why It Matters?

The RMAT designation accelerates the development of AAV-GAD, which could bring this groundbreaking therapy to market faster, offering hope for Parkinson's patients whose traditional treatments no longer work effectively.

Disease modification, meaning halting or delaying disease progression,  is a key differentiator for AAV-GAD. Unlike typical Parkinson’s treatments, which only manage symptoms, AAV-GAD aims to change the course of the disease itself, a significant breakthrough in treating this debilitating condition.

Why It Matters for MeiraGTx?

For MeiraGTx, this milestone represents a major leap in their clinical and regulatory journey. In addition to the RMAT designation, Hologen AI’s involvement has been instrumental in identifying disease-modifying changes in the brain, further validating AAV-GAD's potential. This, combined with MeiraGTx’s ongoing engagement with the FDA and UK regulators, enhances the company’s position to fast-track development and approval.

This is MeiraGTx’s second RMAT designation in almost as many months, having announced the award for it’s AQP1-programme for the treatment of Grade 2/3 radiation-induced xerostomia in March this year.

The company’s impressive portfolio is backed by 4 Rare Pediatric Disease Designations (RPDD), 5 Orphan Drug statuses, one MHRA Specials License and now 2 RMAT designations, and validate its leadership in gene therapies.

With substantial investor backing from Johnson & Johnson, Sanofi, and Eric Schmidt’s Hologen AI, MeiraGTx is aiming to deliver transformative treatments that could reshape the future of Parkinson's disease and other rare genetic disorders.

To learn more about MeiraGTx's equity story, explore the showcase here

  • Curation Connect is an information service provided by Curation Corporation. General disclaimer and copyright This weekly briefing has been commissioned by MeiraGTx and prepared and issued by Curation Connect, in consideration of a fee payable by Curation Connect. Fees are paid upfront in cash without recourse. Curation may seek additional fees for the provision of related IR services for the client but does not get remunerated for any investment banking services. We do not take payment in stock, options or warrants for any of our services. Liability Your investments are your responsibility. No liability whatsoever is accepted by Curation Corporation Limited or any Curation Corporation company of their respective directors, officers, employees or analysts for any loss, whether direct, indirect, special, incidental or consequential, arising whether directly or indirectly as a result of the recipient acting or not acting on any information in any Curation Connect publication, including, without limitation, lost profits arising from the use of the Curation Connect service or any of its publications. We have no liability for any loss of profit, loss of revenue, loss of business, business interruption, loss of opportunity or any indirect, special or consequential loss; any losses which arise from any event beyond our reasonable control; any losses which could not reasonably have been anticipated; or your inability to access and/or use the Curation Connect service or the website. We do not exclude or limit in any way our liability to you where it would be unlawful to do so. Disclaimer Curation Connect publications are provided for general information purposes only and should not be regarded as an offer, solicitation, invitation, inducement or recommendation relating to the subscription, purchase or sale of any security or other financial instrument or investment. This report is intended only for investors who are 'professional clients' as defined by the FCA, and may not, therefore, be redistributed to other classes of investors. This document is provided for information purposes only and should not be regarded as an offer, solicitation, invitation, inducement or recommendation relating to the subscription, purchase or sale of any security or other financial instrument. This document does not constitute, and should not be interpreted as, investment advice. You must carry out your own independent research and obtain suitable professional advice before making any investment decision. The Curation Connect publications do not take the specific needs, investment objectives and financial situation of any particular individual into consideration and we cannot state whether any investment mentioned is suitable for you. You should not base any investment decision solely on the basis of the information we publish or provide to you. Always be aware of market risks – never invest money you cannot afford to lose. All investments can go down as well as up. Investing in securities entails risks. Potential Conflicts of Interest Curation Connect or its respective directors, officers, employees, contributors and clients may have or take positions in the securities, entities or investments mentioned in the Curation Connect publications. Any of these circumstances could create, or be perceived as creating, conflicts of interest. Privacy and Registration All information received from you and your use of the Curation Connect service and the website will be used by Curation Corporation Limited in accordance with our Privacy Policy. Please read this for details of how we may process your personal data. On registration for the Curation Connect service, you must provide us with accurate, complete registration information and it is your responsibility to update and maintain changes to your information. Curation Connect, a trading name of Curation Corporation Limited, is entitled to rely on any information you provide to us. Read our full T&Cs, disclaimersand privacy notice. Contact us at info@curationcorp.com Curation Corporation Limited, 58 Borough High Street, London, SE1 1XF, UK

Other

Articles you might like

Go to blog